Nimotuzumab in the Management of Carcinoma of Cervix: A Case Report

Survival is poor with conventional treatment especially in patients with advanced cervical cancer. In this case report, a 51-years-old patient of cervical cancer with large cervical mass invading the uterine body and left terminal ureter was treated with neoadjuvant chemoradiotherapy followed by concurrent chemoradiotherapy. Weekly Nimotuzumab 200 mg was administered during neoadjuvant chemotherapy as well as concurrent chemoradiotherapy. At the end of the treatment patient showed no evidence of disease. Disease recurred after one and half years and patient was treated with weekly nab-paclitaxel along with the Nimotuzumab for 16 weeks. Patient had no evidence of disease and is healthy, comfortably doing daily activities after 4 years of treatment. Use of Nimotuzumab in this patient of cervical cancer was safe and showed excellent outcomes.

Author(s):

Shyamji Rawat

Abstract | Full-Text | PDF

Share this